{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:34:02Z","timestamp":1769164442333,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T00:00:00Z","timestamp":1530489600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005632","name":"Forest Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005632","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.rmed.2016.05.007","type":"journal-article","created":{"date-parts":[[2016,5,8]],"date-time":"2016-05-08T11:55:30Z","timestamp":1462708530000},"page":"41-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Long-term safety of aclidinium bromide\/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD"],"prefix":"10.1016","volume":"116","author":[{"given":"James F.","family":"Donohue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weily","family":"Soong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pomy","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejhandra","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2016.05.007_bib1","author":"Global Initiative for Chronic Obstructive Lung Disease"},{"key":"10.1016\/j.rmed.2016.05.007_bib2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2125.1986.tb02956.x","article-title":"In\u00a0vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta-adrenoceptor agonists and theophylline","volume":"22","author":"Goldie","year":"1986","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.rmed.2016.05.007_bib3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1183\/09059180.00009902","article-title":"Reducing cholinergic constriction: the major reversible mechanism in COPD","volume":"15","author":"Brusasco","year":"2006","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.rmed.2016.05.007_bib4","series-title":"Anoro\u00ae Ellipta\u00ae Summary of Product Characteristics","author":"GlaxoSmithKline","year":"2015"},{"key":"10.1016\/j.rmed.2016.05.007_bib5","series-title":"Ultibro\u00ae Breezhaler\u00ae Summary of Product Characteristics","author":"Novartis Pharmaceuticals Ltd","year":"2015"},{"key":"10.1016\/j.rmed.2016.05.007_bib6","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1183\/09031936.00225511","article-title":"Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study","volume":"40","author":"Jones","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2016.05.007_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/15412555.2012.661492","article-title":"Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)","volume":"9","author":"Kerwin","year":"2012","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2016.05.007_bib8","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40261-013-0138-1","article-title":"ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients","volume":"33","author":"Rennard","year":"2013","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.rmed.2016.05.007_bib9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.rmed.2007.09.011","article-title":"Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease","volume":"102","author":"Berger","year":"2008","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2016.05.007_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/COPD.S1059","article-title":"Formoterol in the management of chronic obstructive pulmonary disease","volume":"3","author":"Steiropoulos","year":"2008","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.rmed.2016.05.007_bib11","series-title":"Summary of Product Characteristics Duaklir\u00ae Genuair\u2122 340\u00a0\u03bcg\/12 \u03bcg Inhalation Powder","author":"AstraZeneca PLC","year":"2015"},{"key":"10.1016\/j.rmed.2016.05.007_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12931-014-0123-0","article-title":"Efficacy and safety of fixed-dose combinations of aclidinium bromide\/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study","volume":"15","author":"D\u2019Urzo","year":"2014","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2016.05.007_bib13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2466-14-178","article-title":"Efficacy and safety of aclidinium bromide\/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study","volume":"14","author":"Singh","year":"2014","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.rmed.2016.05.007_bib14","series-title":"Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels","author":"The Criteria Committee for the New York Heart Association","year":"1994"},{"key":"10.1016\/j.rmed.2016.05.007_bib15","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1183\/09031936.00136014","article-title":"Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)","volume":"45","author":"Buhl","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2016.05.007_bib16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1465-9921-15-78","article-title":"Safety and tolerability of once-daily umeclidinium\/vilanterol 125\/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study","volume":"15","author":"Donohue","year":"2014","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2016.05.007_bib17","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.rmed.2010.06.004","article-title":"A\u00a0one-year trial of tiotropium Respimat plus usual therapy in COPD patients","volume":"104","author":"Bateman","year":"2010","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2016.05.007_bib18","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1183\/09031936.00040712","article-title":"Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study","volume":"40","author":"Kerwin","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2016.05.007_bib19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1185\/03007995.2013.858618","article-title":"Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies","volume":"30","author":"D\u2019Urzo","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.rmed.2016.05.007_bib20","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.rmed.2011.04.016","article-title":"Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients","volume":"105","author":"Tashkin","year":"2011","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2016.05.007_bib21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","article-title":"Minimal clinically important differences in pharmacological trials","volume":"189","author":"Jones","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2016.05.007_bib22","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejphar.2015.05.020","article-title":"Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy","volume":"761","author":"Calzetta","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.rmed.2016.05.007_bib23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1513\/pats.200409-045MS","article-title":"Distribution of receptor targets in the lung","volume":"1","author":"Barnes","year":"2004","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.rmed.2016.05.007_bib24","series-title":"Poster Presented at the European Respiratory Society, Munich, Germany, 6\u201310","article-title":"Safety of aclidinium bromide\/formoterol fumarate fixed dose combination (FDC) in COPD: pooled analyses of three phase III studies","author":"Korn","year":"2014"},{"key":"10.1016\/j.rmed.2016.05.007_bib25","series-title":"Summary of Product Characteristics","author":"Novartis Pharmaceuticals Ltd, Foradil","year":"2013"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461111630083X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461111630083X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:34:21Z","timestamp":1760614461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095461111630083X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":25,"alternative-id":["S095461111630083X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2016.05.007","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety of aclidinium bromide\/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2016.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}